Overview / Abstract: |
Target Audience Statement of Need/Program Overview Providing real-time interactions and convenience to busy clinicians, the 4-part online summit includes a combination of live and on-demand sessions designed to explore the use of biomarker testing to assess disease risk, new and emerging therapeutic options, treatment-related adverse events, and strategies for selecting the most appropriate treatment for each patient. Session 1 (on-demand): “Utilizing Biomarkers to Navigate Treatment Decisions for Prostate Cancer Patients,” will examine the role of biomarkers in predicting patients’ risk for prostate cancer and prognosis to determine the optimal treatment choice. Session 2 (live and on-demand): “Integrating New Therapies in the Management of Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC),” will explore the diagnosis of nmCRPC, updates to the evidence-based guidelines for its treatment, and the latest clinical data on antiandrogen agents. Session 3 (live and on-demand): “Optimizing Treatment for Patients with metastatic Castration-Resistant Prostate Cancer (mCRPC),” will review strategies for risk stratification of patients, current and emerging therapies, and the selection, initiation, monitoring, and sequencing of treatment for mCRPC. Session 4 (on-demand): “PARP Inhibition: A New Paradigm in Prostate Cancer Care,” will take a closer look at the utility of PARP inhibitors in the treatment of prostate cancer and discuss the selection of patients who are most likely to benefit from this treatment option. Educational Objectives Review the role of PARP inhibitors in prostate cancer treatment and hot to mitigate adverse events associated with this therapy |
Expiration |
Dec 14, 2021 |
Discipline(s) |
Physician CME |
Format |
Online |
Credits / Hours |
0.5 |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Neal D. Shore MD, FACS |
Sponsors / Supporters / Grant Providers |
Advanced Accelerator Applications USA, Inc., Astellas, Clovis Oncology, Inc., Dendreon, Exact Sciences, Myriad Genetics, and Sanofi Genzyme |
Keywords / Search Terms |
Relias LLC Relias, Free CME, Prostate Cancer Free CE CME |